- Home
- BBAI vs NUVB Comparison
BBAI vs NUVB Comparison
Compare BBAI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAI
- NUVB
- Stock Information
- Founded
- BBAI 2020
- NUVB 2018
- Country
- BBAI United States
- NUVB United States
- Employees
- BBAI N/A
- NUVB N/A
- Industry
- BBAI EDP Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- BBAI Technology
- NUVB Health Care
- Exchange
- BBAI Nasdaq
- NUVB Nasdaq
- Market Cap
- BBAI 1.1B
- NUVB 959.2M
- IPO Year
- BBAI N/A
- NUVB N/A
- Fundamental
- Price
- BBAI $4.41
- NUVB $2.58
- Analyst Decision
- BBAI Buy
- NUVB Strong Buy
- Analyst Count
- BBAI 4
- NUVB 6
- Target Price
- BBAI $4.50
- NUVB $7.00
- AVG Volume (30 Days)
- BBAI 49.1M
- NUVB 2.8M
- Earning Date
- BBAI 03-06-2025
- NUVB 02-27-2025
- Dividend Yield
- BBAI N/A
- NUVB N/A
- EPS Growth
- BBAI N/A
- NUVB N/A
- EPS
- BBAI N/A
- NUVB N/A
- Revenue
- BBAI $154,972,000.00
- NUVB $2,162,000.00
- Revenue This Year
- BBAI $13.47
- NUVB N/A
- Revenue Next Year
- BBAI $16.32
- NUVB $369.72
- P/E Ratio
- BBAI N/A
- NUVB N/A
- Revenue Growth
- BBAI 0.01
- NUVB N/A
- 52 Week Low
- BBAI $1.17
- NUVB $1.52
- 52 Week High
- BBAI $5.20
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- BBAI 59.79
- NUVB 45.02
- Support Level
- BBAI $2.85
- NUVB $2.47
- Resistance Level
- BBAI $4.79
- NUVB $2.77
- Average True Range (ATR)
- BBAI 0.54
- NUVB 0.23
- MACD
- BBAI -0.03
- NUVB -0.04
- Stochastic Oscillator
- BBAI 66.17
- NUVB 13.30
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).